Correction to: Nature Medicine https://doi.org/10.1038/s41591-018-0016-8, published online 30 April 2018.
In the version of this article originally published, an asterisk was omitted from Fig. 1a. The asterisk has been added to the figure.
Additionally, a “NOTCH2” label was erroneously included in Fig. 4a. The label has been removed.
The errors have been corrected in the PDF and HTML versions of this article.
About this article
Cite this article
Chapuy, B., Stewart, C., Dunford, A.J. et al. Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med 24, 1290–1291 (2018). https://doi.org/10.1038/s41591-018-0097-4
Addition of Lenalidomide to R-CHOP Improves Outcomes in Newly Diagnosed Diffuse Large B-Cell Lymphoma in a Randomized Phase II US Intergroup Study ECOG-ACRIN E1412
Journal of Clinical Oncology (2021)
Frontiers in Oncology (2020)
Abemaciclib, a CDK4/6 inhibitor, exerts preclinical activity against aggressive germinal center‐derived B‐cell lymphomas
Cancer Science (2020)
Improved personalized survival prediction of patients with diffuse large B-cell Lymphoma using gene expression profiling
BMC Cancer (2020)